Navigation Links
Sinovac Reports Unaudited Second Quarter Financial Results
Date:8/14/2014

="prnews_span">449Total current liabilities49,157

64,597Deferred government grants

4,746

4,588Long-term debt

32,146

11,651Deferred revenue

11,005

10,639Total long term liabilities47,897

26,878Total liabilities97,054

91,475Commitments and contingencies EquityPreferred stock

-

-Common stock

56

56Additional paid-in capital

107,393

107,868Accumulated other comprehensive income

14,141

12,039Statutory surplus reserves

11,808

11,808Accumulated deficit

(4,714)

(6,958)Total stockholders' equity128,684

124,813Non-controlling interests

14,955

14,317Total equity143,639

139,130Total liabilities and equity240,693

230,605 SINOVAC BIOTECH LTD.  Consolidated Statements of Comprehensive Incom
'/>"/>

SOURCE Sinovac Biotech Ltd.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results
2. Sinovac to Participate in UBS Asia Healthcare CEO Summit in November 2013
3. Sinovac Biotech Receives GMP Certification for Mumps Vaccine Production Facility
4. Sinovac to Present at 55th Annual BioPharma China Convention 2012 - Vaccine & Antibody Focus
5. Sinovac Announces Resignation of Chup Hung Mok from Board of Directors
6. Pressure BioSciences, Inc. Reports Second Quarter 2014 Financial Results and Provides Business Update
7. RXi Pharmaceuticals Reports Financial Results for the Second Quarter of 2014
8. Synthetic Biologics Reports Second Quarter 2014 Financial Results and Operational Highlights
9. MarketResearch.com: New Biotechnology Market Research Reports Added to Kalorama Information Knowledge Center
10. GenVec Reports Second Quarter 2014 Financial Results
11. BioSpecifics Technologies Corp. Reports Second Quarter 2014 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... NEW BRUNSWICK, N.J. , March 30, 2015 /PRNewswire-USNewswire/ ... research and innovation projects in the state of ... to its next round of grant funding, announced ... existing New Jersey Health Foundation Research Grants program, an ... to $35,000 each to fund early stage research projects ...
(Date:3/30/2015)...    Intrexon Corporation (NYSE: XON ... Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, ... exclusive strategic collaboration and license agreement to develop ... therapies. This collaboration advances Merck Serono,s comprehensive, science-driven ... immune system,s natural ability to fight tumors. ...
(Date:3/30/2015)... 2015  Naldemedine, an investigational peripherally acting mu-opioid ... Co., Ltd., met its primary and secondary endpoints ... the treatment of opioid-induced constipation (OIC) in adult ... Study results showed that naldemedine (0.2 mg tablet ... of spontaneous bowel movement (SBM) compared with placebo ...
(Date:3/29/2015)... , March 29, 2015  Caris ... study data in small cell cervical cancer ... Caris Molecular Intelligence®, the company,s panomic, comprehensive ... gene mutations which may explain sensitivities and ... that identification of certain biomarkers may guide ...
Breaking Biology Technology:New Jersey Health Foundation Announces An Additional $1 Million To Fund Innovation and Research Grants in New Jersey 2Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 2Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 4Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Study Using Caris Molecular Intelligence Multiplatform Tumor Profiling Identifies Potential Treatment Strategies for Small Cell Cervical Cancer 2Study Using Caris Molecular Intelligence Multiplatform Tumor Profiling Identifies Potential Treatment Strategies for Small Cell Cervical Cancer 3
... - Angiotech Pharmaceuticals,Inc. (NASDAQ: ANPI , ... device company, today announced unaudited interim and ... and year ended,December 31, 2007. The unaudited ... potential adjustment as described under the section ...
... million to $360 million, WARSAW, Ind., Feb. 14 ... provider of products to the global orthopedic,device industry and ... of $79.1 million. The Company stated that,additional financial results ... previously announced on October 4, 2007, the Company,s Audit,Committee ...
... Experience in Biopharmaceutical Manufacturing, Engineering, Technical Services and ... ... 14 Laureate Pharma, Inc., a,full-service biopharmaceutical development and protein production ... In this newly created position, Mr. Swan will be responsible,for leading ...
Cached Biology Technology:Angiotech announces results for the fourth quarter ended December 31, 2007 2Angiotech announces results for the fourth quarter ended December 31, 2007 3Angiotech announces results for the fourth quarter ended December 31, 2007 4Angiotech announces results for the fourth quarter ended December 31, 2007 5Angiotech announces results for the fourth quarter ended December 31, 2007 6Angiotech announces results for the fourth quarter ended December 31, 2007 7Angiotech announces results for the fourth quarter ended December 31, 2007 8Angiotech announces results for the fourth quarter ended December 31, 2007 9Angiotech announces results for the fourth quarter ended December 31, 2007 10Angiotech announces results for the fourth quarter ended December 31, 2007 11Angiotech announces results for the fourth quarter ended December 31, 2007 12Angiotech announces results for the fourth quarter ended December 31, 2007 13Angiotech announces results for the fourth quarter ended December 31, 2007 14Angiotech announces results for the fourth quarter ended December 31, 2007 15Angiotech announces results for the fourth quarter ended December 31, 2007 16Angiotech announces results for the fourth quarter ended December 31, 2007 17Angiotech announces results for the fourth quarter ended December 31, 2007 18Angiotech announces results for the fourth quarter ended December 31, 2007 19Angiotech announces results for the fourth quarter ended December 31, 2007 20Angiotech announces results for the fourth quarter ended December 31, 2007 21Angiotech announces results for the fourth quarter ended December 31, 2007 22Angiotech announces results for the fourth quarter ended December 31, 2007 23Angiotech announces results for the fourth quarter ended December 31, 2007 24Symmetry Medical Reports Preliminary Fourth Quarter Revenue 2Symmetry Medical Reports Preliminary Fourth Quarter Revenue 3Symmetry Medical Reports Preliminary Fourth Quarter Revenue 4Laureate Pharma Appoints Gary Swan as Vice President of Operations 2
(Date:3/12/2015)... The mascots of the Atlantic Coast Conference ... Wake Forest Baptist Medical Center. They stopped by as ... Men,s Basketball Tournament. Young patients enjoyed bonding with their ... autographs. Brenner Children,s Hospital is the pediatric ... children,s hospital in northwest North Carolina ...
(Date:3/11/2015)... 11, 2015 Research and Markets ( ... "Access Control Market by Product, Application & By Geography ... to their offering. , This report predicts ... $10.4 billion by 2020, with an estimated CAGR of ... the products types such as contact cards & readers, ...
(Date:3/10/2015)... Transforming How We Look at ... in Human Space Flight" by Michael A. ... Ph.D. was recently featured by Springer Science Media, highlighting the ... Specifically, "Personalized Medicine in Human Space Flight" was ... 2013 and 2014 from Springer in the journal ...
Breaking Biology News(10 mins):Global Access Control (Cards & Readers, Biometrics, Controllers, Management Software) Market 2015-2020 - Analysis of the $10 Billion Market 2"Personalized Medicine in Human Space Flight" Listed Among Most Influential Papers of 2013 and 2014 2
... Case Western Reserve University have found a way to create ... the developing heart in an animal model a key ... begun testing the technology to uncover how alcohol, drugs and ... in newborn humans. Passing blood cells drag on ...
... to rice cultivation built in the middle basin of the ... various migratory dabbling duck species to significantly increase in number ... that Vegas Altas del Guadiana is turned into a new ... populations are in decline and the loss of natural wetland ...
... - People tend to think of ozone as something ... from UV radiation. At the ground level, however, ozone ... Lisa Ainsworth, a University of Illinois associate professor of ... biologist, said that establishing the exposure threshold for damage ...
Cached Biology News:Finding triggers of birth defects in an embryo heart 2Ducks flock to Extremadura thanks to its ricefields 2Ducks flock to Extremadura thanks to its ricefields 3Ozone's impact on soybean yield: Reducing future losses 2Ozone's impact on soybean yield: Reducing future losses 3
... to offer the ATTO-TAG series of ... primary amines. Developed by Novotny and ... reagents are similar to the important ... anthracene-2,3-dicarboxaldehyde, all of which are also ...
Troponin I Immunogen: Full length native protein (purified) (Human). Storage: -20 C, Avoid Freeze/Thaw Cycles...
Corticoliberin...
...
Biology Products: